PEP-Therapy owns IP rights for the exploitation of an innovative technology called CP&IP (Cell Penetrating & Interfering Peptides). These innovative peptides penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
Two major innovations have been combined in a single bi-functional peptide to target efficiently and accurately key cellular mechanisms involved in pathologies:
Optimized Cell Penetrating Peptides (CPP), as a "shuttle" to deliver drugs pharmaceutically active peptides into the cell and also into specific organelles;
Short Interfering peptides specifically designed to target relevant protein/protein interactions, thus blocking key mechanisms of diseases, with no effect on other physiological functions of the two proteins.
The combination of both functionalities has led to the development of a unique technology with intracellular uptake and targeting, good in vivo stability and safety profile, and the versatility to address hard-to-reach intracellular targets, with high specificity in multiple pathologies.
Based on the proof-of-concept on lead product, PEP-Therapy will reinforce its product pipeline based on the CP&IP technology.
Our CP&IP technology can be applied to other new peptide projects for in-licensing.